28 June-1 July Barcelona
1-O | NALIRIFOX versus nab-paclitaxel gemcitabine in treatment-naive patients with mPDAC: additional results from the phase 3 NAPOLI 3 trial | Emma Page | Received |
1-SO | A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma | NAIMAH BOLAJI | Received |
1-P | Gastric cancer: Artificial intelligence, complex system analysis and simulation for best management | Oleg Kshivets | Received |
2-PD | Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies | IRBLleida IRBLleida | Received |
2-SO | Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with idh1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial | Steve Waye | Received |
3-SO | Clinical relevance and actionability of BRAF alterations in advanced biliary tract cancer: preliminary results from the multicenter B-REAL study | Monica Niger | Received |
4-PD | Deep learning of pancreatic cancer histopathology images predicts recurrence after surgery | Avelyn Wong | Received |
4-SO | Impact of molecular profiling on survival in patients with advanced biliary tract cancers | Leony Antoun | Received |
5-SO | Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study | Rebecca Oakes | Received |
5-PD | MONEO: Phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC) | Maria Alsina | Received |
5-P | A Soluble resistance related calcium binding protein (Sorcin) up-regulates in the multi-drug resistant advanced gastric cancer patients | Sushmita Ghosh | Received |
7-PD | Osemitamab plus capecitabine and oxaliplatin (CAPOX) as the first line treatment of advanced G/GEJ cancer-updated efficacy data per claudin 18.2 expression level from study TranStar102/TST001-1002-cohort C | Sue Chen | Received |
7-P | Change in CA 19-9 after 8 weeks of first-line chemotherapy as a predictor of overall survival in patients with metastatic pancreatic ductal adenocarcinoma | Jarrod Smith | Received |
8-PD | HERIZON: A Phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2 advanced stomach Cancer-Correlation of the antibody responses and clinical outcome | Joshua Tobias | Received |
9-PD | Anti-HER2 therapy following ctDNA-identified ERBB2 amplification for patients with advanced gastric cancer: exploration of real-world outcomes and resistance mechanisms | Sakti Chakrabarti | Received |
9-O | Health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial | Steve Waye | Received |
10-SO | Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification | Rebecca Oakes | Received |
11-SO | Bemarituzumab for the Treatment of Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer: Final Analysis of a Randomized Phase 2 Trial (FIGHT) | Utkarsha Singh | Received |
12-PD | Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort | Marjolein Lansbergen | Received |
13-SO | Outcomes and a prognostic classifier in 130 patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade | Giovanni Randon | Received |
13-P | Management of Metastatic Colorectal Cancer in Patients &8805;70 Years - A Single Center Experience | Florian Huemer | Received |
14-SO | Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age =65 years subgroup | Megan Fox | Received |
15-PD | Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments | Mara Persano | Received |
16-P | Associations among patient-physician sex concordance, treatment practices, and survival outcomes in a population-based colon cancer cohort | Philip Ding | Received |
17-P | Impacts of patient-reported non-hormonal symptoms on outcomes of patients with neuroendocrine neoplasms (NENs) | Michael Sawyer | Received |
17-PD | Multicentric prospective study assessing clinical benefit of targeted treatment for patients with biliary tract cancers | Monica NIger | Received |
19-PD | Finnish population-based metastatic colorectal cancer data collection study - comparison with the prospective RAXO study | Pia Osterlund | Received |
20-P | Pseudoglandular pattern in hepatocellular neoplasms and its diagnostic value with cytokeratin immunostain | Lee-Ching Zhu | Received |
21-P | GastroPanel: A blood test to triage dyspeptic patients with atrophic gastritis at risk of developing gastric adenocarcinoma | Cinzia Papadia | Received |
21-PD | Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in metastatic colorectal cancer (mCRC) patients | Martina Carullo | Received |
22-PD | RAS-mutations in population-based and real-life metastatic colorectal cancer cohorts | Emerik Osterlund | Received |
22-P | Frequency of dihydropyrimidine dehydrogenase (DPD) deficiency detection and adverse events in patients receiving fluoropyrimidine-based therapy in a pancreatic and biliary tract cancer cohort | Eve Wilson | Received |
22-SO | Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study | Federica Marmorino | Received |
23-P | Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP Follow-up Study | Hiroki Sameshima | Received |
23-SO | The influence of the microbiome on the tumour-immune microenvironment in colorectal cancer | Rachel Purcell | Received |
25-PD | Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colo-rectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study | Martin Köhler | Received |
26-PD | Efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal versus gastric cancers: a large, multicenter, cohort study | Giacomo Mazzoli | Received |
27-SO | Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO | Veronica Conca | Received |
27-PD | The use of pre-operative systemic oxaliplatin or irinotecan doublet chemotherapy in colorectal cancer peritoneal metastases (CRPM): Results from a single UK peritoneal tumour centre | Nadina Tinsley | Received |
28-P | Locally advanced gastric cancer under FLOT - Real-world data on efficacy of patients with dMMR | Lisa Goncalves | Received |
28-PD | Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis | ANDRE Thierry | Received |
31-P | A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors | Maria Apostolopoulou | Received |
32-SO | Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT) | Marco Germani | Received |
33-P | The role of preoperative immune-chemotherapy in locally advanced resectable gastric cancer with microsatellite instability | Henian Sun | Received |
35-P | Zanzalintinib (XL092) in combination with atezolizumab for previously treated metastatic colorectal cancer | Jennifer Humbert | Received |
48-P | Outcomes of early gall bladder cancer (GBCA): A retrospective analysis from a tertiary care centre in India | Joydeep Ghosh | Received |
49-P | Stereotactic body radiotherapy (SBRT) for liver metastasis. Institutional experience | Maria Vera Merino | Received |
51-P | Epigenome-wide DNA methylation profiling identifies the TNXB gene as a potential epigenetic candidate for colorectal cancer prevention | Manuel Macias Gonzalez | Received |
54-P | Circulating immune cells as a tool to predict benefit from atezolizumab/bevacizumab in advanced hepatocellular carcinoma (aHCC) | Francesca Salani | Received |
56-P | Brightline-2: a Phase IIa/IIb, open-label trial of the MDM2p53 antagonist brigimadlin (BI 907828) in patientswith advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinomaor other ed solid tumours | Teresa Macarulla | Received |
57-P | Atezolizumab in combination with bevacizumab in patients with unresectable HCC previously untreated with systemic therapy: Interim analysis results from phase IIIb Italian AMETHISTA trial | Cinzia Astolfi | Received |
58-P | An ongoing open-label, phase 2 trial of RP2 or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma | Leilany Lopez | Received |
60-P | Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: A single-arm phase II clinical trial | Ting Liu | Received |
63-P | Real-world UK retrospective multi-centre review of the use of G-CSF in the prevention of chemotherapy-induced neutropenia in patients with CRC receiving trifluridine/tipiracil | Laura bell | Received |
67-P | Immune cell and microbiome contributions to radiotherapy response in rectal cancer | Rachel Purcell | Received |
68-P | Impact of specimens and fixation status on HER2 assessment in the treatment of advanced gastric cancer (HER_WEEKEND study) | Michio Nakamura | Received |
77-P | Multisite intratumoral chemotherapy improves treatment outcome in a murine model with pancreatic ductal adenocarcinoma | Ron Epelbaum | Received |
80-P | Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study | Takeshi Yamada | Received |
82-P | Impact of COVID-19 pandemic on metastatic colorectal cancer outcomes | Mirjana Pavlovic Mavic | Received |
90-P | Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment | Guglielmo Vetere | Received |
91-P | Landscape of BRAF-V600E mutant colorectal cancer management in Latin America | Juan Manuel OConnor | Received |
93-P | Safety and feasibility of irradiation and nivolumab in esophageal cancer a phase I/II study | Geir Olav Hjortland | Received |
95-P | Long-term effectiveness results and prognostic predictors for overall survival from CIREL the real-world multi-centre, observational cohort on irinotecan-eluting transarterial chemoembolization in CRLM | Bleranda Zeka | Received |
96-P | Circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer treated with multimodal treatment | Lorenzo Gervaso | Received |
99-P | Tumor treating fields (TTFields) are effective for treatment of gastric cancer cells, boosting the activity of FOLFOX | Sinead Stewart | Received |
104-P | Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001) | Huimin Wang | Received |
105-P | COLSTAR study: Safety data on the first cohort of patients from the safety lead-in part of the study | Steve Waye | Received |
108-P | An interplay between immune cells and microbiota drives the spontaneous regression of colorectal polyps in familial adenomatous polyposis pig model | Wei Liang | Received |
110-P | Epidemiological and clinicopathological features of early- (EOPC) and late-onset pancreatic cancer (LOPC) patients (pts): A mono-institutional retrospective analysis | Maria Bensi | Received |
112-P | Assessing the accuracy of CT staging for tumor and nodal staging in colon cancer | Jingjing Yu | Received |
113-P | Evidence for early detection of metastatic variants and tumour evolution in ctDNA of patients with oesophageal adenocarcinoma | Mark Openshaw | Received |
114-P | The therapeutic potential of nuclear receptor RORy in hepatocellular carcinoma | Sabrina Leo | Received |
116-P | Clinical utility of circulating tumor DNA (ctDNA) in patients with early/resected biliary tract cancer (BTC) | James Yu | Received |
117-P | Feasibility of tumor-informed circulating tumor DNA in neoadjuvant rectal cancer | Charuta Palsuledesai | Received |
118-P | Clinical significance of primary tumor sites and epithelial tumor markers in patients with unresectable/recurrent gastrointestinal neuroendocrine carcinoma treated with combined chemotherapy with irinotecan and cisplatin | Koshiro Fukuda | Received |
119-P | HGCSG 1803: single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment | Kentaro Sawada | Received |
120-P | Efficacy of systemic therapy for advanced hepatocellular carcinoma based on etiology: a systematic review and network meta-analysis | Charlene Hoi Lam Wong | Received |
123-P | CD73high biliary tract cancer (BTC) is a molecularly defined subtype with distinct clinical implications | Pietro Carotenuto | Received |
126-P | TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: substudies in gastric and colorectal cancer | Sian Budgen | Received |
131-P | Evaluation of predictive factors of toxicity of chemotherapy with FOLFIRINOX in patients treated for pancreatic adenocarcinoma | Roland Eid | Received |
132-P | Underrepresentation of racial and ethnic minorities in metastatic colorectal carcinoma clinical trials within the United States | Tracey Pu | Received |
135-P | Detection of RAS gene mutations in patients with metastatic colorectal cancer during cetuximab-based first-line treatment and survival of the patients in relation to changes in RAS gene status | Marian Stresko | Received |
137-P | Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations | Kelly Corona | Received |
139-P | Total neoadjuvant therapy for locally advanced rectal cancer: a UK cohort | Mayumi Forster | Received |
142-P | Completion of genetic testing and incidence of pathogenic germline mutation among patients with early-onset colorectal cancer, a single institution retrospective analysis | Zhaohui Jin | Received |
144-P | Characterisation of gastric tumour microbiota using isolation culture methodology and a novel gastric tumour bioreactor system | Mary Booth | Received |
146-P | Efficacy and safety of FLOT combined with apatinib and sintilimab as a neoadjuvant therapy regimen for locally advanced gastric or gastroesophageal junction adenocarcinoma: an open-lable, single-arm, phase II study | Huinian Zhou | Received |
153-P | Focus on RAS codon 61 mutations in metastatic colorectal cancer (mCRC): a retrospective analysis | Francesco Schietroma | Received |
154-P | Using the EVendo score to predict varices and varices needing treatment in hepatocellular carcinoma patients planned for atezolizumab-bevacizumab | Ching Han Toh | Received |
156-P | Efficacy and safety of cadonilimab combined with FLOT regimen as a neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma: a prospective, multicenter, open-label, single-arm phase II study | Bo Long | Received |
158-P | The algorithm of esophagectomy technique ion in surgical treatment of squamous cell carcinoma and adenocarcinoma of esophagus | Nikolay Khandogin | Received |
159-P | Association of acrochordons and colorectal polyps: a pilot study to identify potential genetic or viral etiology | Bogdan Gafton | Received |
162-P | Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): a retrospective exploratory study | Jing Huang | Received |
164-P | Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POL?)-mutated solid tumours in the GARNET study | Steve Orlando | Received |
167-P | Type 2 diabetes as a predictive and prognostic factor in advanced pancreatic cancer: preliminary results of the Italian, observational PANCAKE study | Federico Nichetti | Received |
172-P | VOLTAGE cohort D: preoperative chemoradiotherapy followed by consolidation nivolumab plus ipilimumab in patients with locally advanced rectal cancer | Yusuke Takahashi | Received |
173-P | Extended molecular profiling in patients with biliary tract cancers: impact of the brcaness phenotype in patients management | Virginia Genovesi | Received |
174-P | Outcomes in local gastric cancer resected without neoadjuvant therapy: a descriptive study | Elisabet Bujons Buscarons | Received |
175-P | Next-generation sequencing in colorectal cancer patients: characterization and prognostic implications | Federico Longo | Received |
177-P | Italian real world artificial intelligence (AI) based analysis of EaRly-onset COLorEctal cancer: the ERCOLE study | Maria Alessandra Calegari | Received |
180-P | Efficacy and safety of anti-PD1 agents in patients with advanced GI malignancies: real-world data | Sofia Montenegro Luis | Received |
181-P | Adoption of neoadjuvant immunotherapy in patients with deficient mismatch repair localized colorectal cancer: a National Cancer Database analysis | Sakti Chakrabarti | Received |
182-P | Multicenter real-world data of treatment with NALIRI plus 5FU/LV in advanced Spanish pancreatic cancer | Rafael Rafael | Received |
183-P | BRAF mutant metastatic colon cancer expect the unexpected: a single centre study | Mona Hassan | Received |
186-P | Efficacy of the combined chemotherapy regimens in elderly patients with advanced pancreatic cancer | Mariam Manukyan | Received |
187-P | Targeting glutamine metabolism and EGFR in RAS wildtype metastatic colorectal cancer | Kristen Ciombor | Received |
189-P | Surrogate endpoints in advanced gastroesophageal cancer: a systematic review and meta-analysis of phase III clinical trials | IRBLleida IRBLleida | Received |
190-P | NALIRIFOX (liposomal irinotecan 5&8209;fluorouracil/leucovorin oxaliplatin) versus FOLFOX (5&8209;fluorouracil/leucovorin oxaliplatin) as first-line treatment of metastatic pancreatic ductal adenocarcinoma: real-world comparative overall survival analysis | Emma Page | Received |
195-P | Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: a multicenter retrospective real-world study | Carlo Signorelli | Received |
197-P | Clinical outcomes in patients with krukenberg tumors from colorectal cancer | Arsha Ostowari | Received |
202-P | Topical diclofenac in prevention of capecitabine associated HFS in patients with GI cancers: an exploratory subgroup analysis of the D-ToRCH study | Akhil Santhosh | Received |
205-P | Streamlining the diagnostic pathway for Lynch Syndrome in colorectal cancer patients: a ten-year experience in a single Italian center | Alberto Puccini | Received |
207-P | Analysis of chemotherapy-induced subtype shifts in patient-derived tumoroids and parallels to functional in-vitro chemosensitivity testing in pancreatic ductal adenocarcinoma | Tabea Sturmheit | Received |
210-P | Efficacy and tolerability of cetuximab 750 mg/m2 every three weeks in metastatic colorectal cancer | Mohamed Aseafan | Received |
218-P | Oligometastatic Pancreatic Cancer: A Systematic Review and Synthesis of Consensus | Carl-Stephan Leonhardt | Received |
219-P | Non-operative management of localized mismatch repair deficient colon cancer: a real-world perspective | Sakti Chakrabarti | Received |
220-P | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin chemotherapy in the treatment of patients with metastatic colorectal cancer: a meta-analysis | John Kelvin Lalusis | Received |
221-P | Prediction of colon cancer recurrence based on proteomic biomarkers | Soledad Cameselle-Garcia | Received |
231-P | Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2) | Benjamin Weinberg | Received |
232-P | The predictive factors for identifying gastric cancer in patients with gastric indefinite for neoplasia lesions | Hye-Su You | Received |
233-P | Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: a single-center study, updated with new data | Stefani Ioannou | Received |
235-P | Association of stage shift and prior gastroscopy in patients with gastric cancer | Yi-Hsin Yang | Received |
236-P | Aflibercept-based and bevacizumab-based second line regimens in patients with RAS mutant metastatic colorectal cancer: propensity score weighted-analysis from a multicenter cohort | Jessica Lucchetti | Received |
240-P | Frequency and management of trifluridine/tipiracil (FTD/TPI) bevacizumab (BEV)-associated neutropenia in patients with refractory metastatic colorectal cancer (mCRC) in real-world practice | Nieves Martínez Lago | Received |
245-P | Survival after minimally invasive vs open surgery for pancreatic adenocarcinoma | Joris Jaekers | Received |
249-P | Aflibercept-based and bevacizumab-based second line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: propensity score weighted-analysis from a multicenter cohort | Lorenzo Angotti | Received |
251-P | Prospective validation of the Asian Pacific Colorectal Screening (APCS) score to detect colorectal neoplasia among Mexican subjects undergoing screening colonoscopy | Monica Meneses-Medina | Received |
252-P | Comparison of second-line treatment after GEM/nab-PTX therapy for metastatic pancreatic cancer | Kotaro Takeshita | Received |
253-P | Single agent immunotherapy in advanced oesophago-gastric (OG) cancer: an option for frail patients | Grisma Patel | Received |
256-P | Albumin-bilirubin (ALBI) grade at 6 weeks post-diagnosis is a better prognosticator than baseline ALBI in intrahepatic cholangiocarcinoma | Chi Fung Wong | Received |
263-P | Epidemiology and characteristics of low or normal AFP vs high AFP in hepatocellular carcinoma- retrospective experience in a tertiary care institute | ANAND PRAVEEN KUMAR A | Received |
266-P | Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI) | Darren Cowzer | Received |
267-P | Spatially resolved detection of premalignant lesions and immune-infiltration in gastric endoscopic biopsies using multiplexed immunofluorescence and correlation with OLGA/OLGIM assessment | Franz Villarroel-Espindola | Received |
268-P | Using 16S rRNA gene sequencing to investigate the composition of Fusobacterium-associated microbiota and its impact on outcome in rectal cancer | Stefania Napoli | Received |
272-P | Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune check-point inhibitor (ICI) therapy | James Harding | Received |
273-P | Genomic alterations associated with aggressive histology and decreased overall survival in neuroendocrine malignancies | Nicole Farha | Received |
275-P | FOLFOX versus FOLFIRI as second-line treatment after cisplatin-gemcitabine in patients with advanced biliary tract cancers | Federico Nichetti | Received |
276-P | Robust and cost effective in-vivo CAM models for drug combination study in colorectal cancer during covid-19 pandemic | razia aslam | Received |
277-P | Real-world efficacy, safety, and impact of the GIPI score of nivolumab in advanced esophageal squamous cell carcinoma (ESCC) refractory or intolerant to prior chemotherapy in European population: the EPIC trial | Antía Cousillas Castiñeiras | Received |
278-P | Survival impact and predictive scores for thrombosis associated with pancreatic ductal adenocarcinoma (PDAC) | Alejandra Romano | Received |
281-P | Safety analysis and preliminary clinical results of REPROGRAM-01 phase II study evaluating regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer | Angélique Vienot | Received |
282-P | Atezolizumab and bevacizumab in the treatment of advanced hepatocellular carcinoma - a single-center experience | Nika Librenjak | Received |
284-P | Stereotactic body radiotherapy (SBRT) for liver metastasis of colorectal and anal cancer patients: clinical outcomes of a single centre experience | Berta Martin-Cullell | Received |
285-P | Basket trials in upper gastrointestinal and hepato-pancreatico-biliary cancers an emerging entity | Prerana Huddar | Received |
287-P | Retrospective real-world data study using natural language processing to describe treatment sequence and clinicopathological patterns in patients with metastatic colorectal cancer in five Spanish institutions | Elena Garcia Arcelay | Received |
290-P | Treatment sequences and locoregional therapies for patients with carcinoid and refractory carcinoid syndrome. A multicentric cohort analysis | ANA ISABEL OVIEDO ALBOR | Received |
291-P | Missing colorectal liver metastases after neoadjuvant chemotherapy: can we improve the prognosis? | Elena Fernandez de Sevilla | Received |
294-P | The outcome of patients with mismatch repair deficient esophagogastric cancer receiving immunotherapy: A systematic review | Sakti Chakrabarti | Received |
300-P | Progression free survival in patients with metastatic colorectal cancer treated with maintenance therapy with bevacizumab adjusted by sideness in a third level hospital in Mexico City | ABDEL KARIM DIP BORUNDA | Received |
307-P | Serial ctDNA monitoring during immunotherapy (IO) in patients (pts) with MSI-H/dMMR advanced colorectal cancer (CRC) | Shoshana Mehler | Received |
311-P | Beyond the binary: Analysis of esophageal cancer hospitalizations in the transgender population in United States | Lekha Yadukumar | Received |
313-P | Impact of COVID-19 on national trends of hospitalization and outcomes in pancreatic cancer patients presenting with venous thromboembolism in the United States | Lekha Yadukumar | Received |
316-P | A retrospective study of gemcitabine with nab-paclitaxel as third line retreatment in advanced pancreatic adenocarcinoma | Tara McSweeney | Received |
320-P | Immune checkpoint inhibitors (ICIs) vs chemotherapy as 3rd line regimen in patients with advanced gastric or esophageal (G/E) adenocarcinoma: A comparative study | Brooke Wietharn | Received |
327-P | Comparison of clinicopathological and molecular features of two rare entities: Appendiceal carcinoma and small bowel adenocarcinoma | Kreina Sharela Vega-Cano | Received |
330-P | ERBB2 mutations in metastatic colorectal cancer: from clinicopathological features to potential treatment implications in a real-world cohort | caterina vaghi | Received |
332-P | Characteristic and clinical outcome of localized gastric cancer; real-world data | Amal AlJuhani | Received |
333-P | Retrospective analysis of second-line chemotherapy after Folfirinox failure in advanced pancreatic cancer | Yana Chikhareva | Received |
336-P | Neoadjuvant chemotherapy of the mFOLFIRINOX in the treatment of resectable pancreatic cancer | Dayana Kantieva | Received |
337-P | Associate factors for endoscopic submucosal disection and postoperative delayed hemorrhage of colorectal neoplasm. | Yong Wook Jung | Received |
338-P | Second line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first line treatment with gemcitabine and nab-paclitaxel | Tara McSweeney | Received |
342-P | Prospective, observational study evaluating the effectiveness and safety of aflibercept plus FOLFIRI in metastatic colorectal cancer (mCRC) according to Polish reimbursement criteria | Ragini Khajuria | Received |
349-P | An evidence-based patient resource program to improve the everyday lives of patients with metastatic gastrointestinal cancer | Alberto Sobrero | Received |
360-P | Efficacy of regorafenib according to extended RAS evaluation: a multicenter retrospective analysis | Giovanni Trovato | Received |
368-P | Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: a multicenter retrospective analysis | Giulia Caira | Received |
374-P | Total neoadjuvant treatment of rectal cancer by MRI-guided radiotherapy | Sven Van Laere | Received |
376-P | CoVigi Phase IV multicentric trial evaluating Covid-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2 specific antibody and T-cell response focused on patients with gastrointestinal tumors | Radka Obermannova | Received |
378-P | Single institute experience of peri-operative FLOT chemotherapy | Vikram Bansal | Received |
379-P | ARID1A as a prognostic biomarker in gastroesophageal cancer: a genomic database analysis | Annalisa Schirizzi | Received |
380-P | Real world survival outcome in gastric cancer in a resource limited setting - an Indian experience | Ruhi Kumar | Received |
381-P | Management of EaRly-onset MetastatIc cOlorectal caNcEr (ERMIONE): a single institution analysis | Giustina Valente | Received |
386-P | Novel data visualization and unsupervised machine learning techniques to support optimal management of toxicity profiles of encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer | Mounia Foucart | Received |
397-P | Progression-free survival with maintenance therapy with fluoropyrimidine in patients with advanced gastric and gastroesophageal junction cancer in a third level hospital in Mexico City | Alberto Pimentel | Received |
402-P | Six-months CA19.9 velocity as a predictive factor for relapse-free survival after curative pancreasectomy in pancreatic cancer | Silvia Cesario | Received |
403-P | Rectal cancer in young patients - single center experience | Vanessa Patel | Received |
408-P | Costa Rica, an example of the Americas in the implementation of an innovative organized colorectal screening program during 2017 2022 | Jeffrey Jacobo | Received |
410-P | Factors affecting progression free survival (PFS) for patients with metastatic colorectal cancer (mCRC) receiving regorafenib or for patients after re-challenge previously effective chemotherapy (CT) regimens in third or following lines | Evgenia Kuzmina | Received |
411-P | Pancreatic cancer oral inverse agonist of RORgT receptor targets primary cancer cells and alters inflammatory mediators of the tumor microenvironment | Lynne Kelley | Received |
415-P | The importance of RAS and BRAF in metastatic colorectal cancer - real world evidence from North-East Romania | Vlad Afrasanie | Received |
419-P | Safety and effectiveness analysis of neoadjuvant chemoradiation plus consolidative chemotherapy with concurrent anti-pd-1 therapy in mid-low locally advanced rectal cancer | Xinliang Liu | Received |
28 June-1 July Barcelona
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|